Monthly Archives: May 2013

Dey, L.P., et al. v. Sunovion Pharmaceuticals, Inc.

Docket No. 2012-1428 NEWMAN, BRYSON, O’MALLEY May 20, 2013 Brief summary: Formal confidentiality agreements are not required to prevent invalidation for public use under 35 U.S.C. 102(b) (pre-2011) as long as “there were ‘circumstances creating a similar expectation of secrecy’” … Continue reading

Posted in Anticipation (35 USC 102), Public Use | Leave a comment

Aventis Pharmaceuticals, Inc. et al. v. Amino Chemicals Ltd., et al.

Docket No. 2011-1335, -1336 NEWMAN, BRYSON(d), REYNA May 20, 2013 Brief summary: The term “substantially pure” was determined to have different meanings when used in the context of chemical intermediates and the end product of the claimed process. Summary: This … Continue reading

Posted in Claim Construction, Generics / ANDA | Leave a comment

Motiva, LLC v. International Trade Commission and Nintendo Co., Ltd. et al.

Docket No. 2012-1252 NEWMAN, PROST, O’MALLEY May 13, 2013 Summary: Motiva appealed ITC decision that Nintendo’s importation of its Wii video game system did not violate § 337 of the Tariff Act of 1930 because “a domestic industry does not … Continue reading

Posted in International Trade Commission | Leave a comment

Bowman v. Monsanto et al.

U.S. Supreme Court No. 11-796 May 13, 2013 Unanimous opinion delivered by J. Kagan Brief summary: The doctrine of patent exhaustion did not exempt farmer who reproduced patented seeds through planting and harvesting from infringement of Monsanto’s patents. Summary: The … Continue reading

Posted in Patent Exhaustion | Leave a comment

Allergan, Inc. v. Sandoz, Inc. et al.

Docket No. 2011-1619, -1620, -1635, -1639 DYK (d), PROST, O’MALLEY May 1, 2013 Brief summary: Claim to method of treatment found not obvious due to “no loss of efficacy” limitation. Summary: Sandoz appealed DC finding that Allergan’s claims related to … Continue reading

Posted in Claim Construction, Generics / ANDA, Obviousness | Leave a comment